NYSE · Healthcare
ABBOTT LABORATORIES (ABT)
As-reported financials and recent SEC filings for ABBOTT LABORATORIES, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$44.33B
Net income
$6.52B
Net margin
14.7%
Diluted EPS
$3.72
ROE
12.4%
P/E (TTM)
24.7×
Market cap
$153.59B
Debt / equity
0.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B |
| Gross profit | $25.01B | $23.24B | $22.13B | $24.51B | $24.54B |
| Operating income | $8.05B | $6.83B | $6.48B | $8.36B | $8.43B |
| Net income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B |
| Diluted EPS | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
SD2026-05-27
View on EDGAR →1442026-05-15
View on EDGAR →SCHEDULE 13G2026-04-29
View on EDGAR →42026-04-29
View on EDGAR →10-Q2026-04-29
View on EDGAR →42026-04-28
View on EDGAR →42026-04-28
View on EDGAR →42026-04-28
View on EDGAR →Go deeper on ABT
Search ABBOTT LABORATORIES’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.